Table of Contents

October 1, 2014 • Volume 20 • Number 19

Highlights of This Issue 4975

SPECIAL FEATURES

Editorial

4977  AACR Cancer Progress Report 2014: Transforming Lives Through Research
       Jesse Potash and Kenneth C. Anderson

Policy Statement

4978  Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research
       Charles L. Sawyers and Laura J. van ’t Veer

CCR Translations

4982  The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
       Antoni Ribas and Paul C. Tumeh
       See related article, p. 5064

CCR New Strategies

4985  New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management
       Approach
       Amer M. Zeidan and Steven D. Gore

CCR Perspectives in Drug Approval

4994  FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAF V600E Mutation
       Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Mikinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, and Richard Pazdur

Molecular Pathways

5001  Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylination in Cancer—Different Paths, Same Destination
       Teresa Ezponda and Jonathan D. Licht

CANCER THERAPY: CLINICAL

5009  A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

5023  Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

5032  Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
       Toshib Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher
Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

Correction: A Severe Combined Immunodeficient–hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma

ABOUT THE COVER
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m² cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.